Our research focuses on the joint management model of community hospitals and a top tier hospital as applied to a large sample of patients with type 2 diabetes mellitus (T2DM) followed-up for 10 years. |
Research has lagged on the development a cardiovascular disease (CVD) risk assessment tool for people with T2DM, and what few tools are currently available have often been copied or borrowed from other risk assessment models. It is therefore necessary to explore CVD risk assessment tools for Chinese patients with T2DM. |
The aim of the Beijing Communities Diabetes Study was to investigate whether multifactorial interventions have a long-term effect on the risk of diabetes-related macro-vascular complications in patients with T2DM living in urban communities of Beijing. It is the first of its kind ever undertaken in China. |
To date, with the major exception of the UK Prospective Diabetes Study, there have been few successful long-term prospective studies of diabetic management in a large sample of patients worldwide. Our results show that multifactorial interventions for CVD risk factors over 10-year lowered the estimated 10-year risk for CVD events in patients with diabetes. |
We suggest the use of the improved Framingham Risk Score (FRS) to stratify a patient’s CVD risk when analyzing the efficacy of management. Aggressive risk reduction should be focused on those individuals with had a strongly improved (FRS) score. |
Introduction
Methods
Study Population and Intervention Methods
Study Procedures
Laboratory Data
Statistical Analyses
Results
Patients characteristics | Framingham Risk Score stratificationa | Statistical quantityb | P valuec | |||
---|---|---|---|---|---|---|
Total (n = 3232 patients) | I-FRS < 10% (n = 204 patients) | I-FRS ~ 10–20% (n = 2531 patients) | I-FRS > 20% (n = 497 patients) | |||
Age (years) | 63.7 ± 10.4 | 45.2 ± 8.8 | 63.5 ± 9.1* | 72.0 ± 6.3*† | 694.40 (F) | < 0.001 |
Gender | ||||||
Male | 1295 (40.07%) | 114 (55.88%) | 1170 (46.23%) | 11 (2.21%) | 357.80 (χ2) | < 0.001 |
Female | 1937 (59.93%) | 90 (44.12%) | 1361 (53.77%) | 486 (97.79%) | ||
Duration of diabetes (years) | 3.8 [0.0, 9.8] | 1.8 [0.0, 5.2] | 3.8 [0.0, 9.7]* | 5.0 [0.0, 11.8]*† | 6.51 (Z) | < 0.001 |
BMI (kg/m2) | 25.4 ± 3.5 | 25.8 ± 4.0 | 25.3 ± 3.5 | 25.3 ± 3.4 | 1.86 (F) | 0.156 |
Waist circumference (cm) | 89.1 ± 9.4 | 88.6 ± 10.0 | 89.1 ± 9.3 | 89.3 ± 9.4 | 0.38 (F) | 0.684 |
Hip circumference(cm) | 99.5 ± 8.6 | 99.9 ± 8.7 | 99.4 ± 8.5 | 99.9 ± 8.6 | 0.96 (F) | 0.383 |
Waist–hip ratio | 0.90 ± 0.06 | 0.89 ± 0.06 | 0.90 ± 0.06 | 0.89 ± 0.07 | 2.77 (F) | 0.063 |
Neck circumference (cm) | 36.5 ± 3.8 | 36.8 ± 3.7 | 36.6 ± 3.8 | 35.7 ± 3.4*† | 11.68 (F) | < 0.001 |
SBP (mmHg) | 129.5 ± 14.7 | 121.0 ± 12.1 | 128.2 ± 14.1* | 139.7 ± 13.8*† | 182.55 (F) | < 0.001 |
DBP (mmHg) | 78.1 ± 8.8 | 78.6 ± 8.1 | 78.0 ± 8.8 | 78.0 ± 9.0 | 0.50 (F) | 0.608 |
Smoker | ||||||
No | 2718 (84.10%) | 187 (91.67%) | 2092 (82.66%) | 439 (88.33%) | 19.33 (χ2) | < 0.001 |
Yes | 514 (15.90%) | 17 (8.33%) | 439 (17.34%) | 58 (11.67%) | ||
FPG (mmol/L) | 7.86 ± 2.63 | 7.57 ± 2.63 | 7.81 ± 2.61 | 8.27 ± 2.68*† | 7.86 (F) | < 0.001 |
Hpg (mmol/L) | 10.71 ± 4.99 | 10.25 ± 3.84 | 10.65 ± 5.15 | 11.24 ± 4.58*† | 3.75 (F) | 0.024 |
HbA1c (%) | 7.3 ± 1.6 | 7.2 ± 1.8 | 7.3 ± 1.6 | 7.8 ± 1.6*† | 22.30 (F) | < 0.001 |
TG (mmol/L) | 1.91 ± 1.40 | 1.86 ± 1.38 | 1.88 ± 1.37 | 2.11 ± 1.56*† | 5.62 (F) | 0.004 |
TC (mmol/L) | 5.20 ± 1.23 | 4.50 ± 0.92 | 5.16 ± 1.21* | 5.72 ± 1.24*† | 82.67 (F) | < 0.001 |
HDL-cholesterol (mmol/L) | 1.34 ± 0.43 | 1.22 ± 0.32 | 1.33 ± 0.42* | 1.42 ± 0.48*† | 16.98 (F) | < 0.001 |
LDL-cholesterol (mmol/L) | 2.95 ± 0.86 | 2.54 ± 0.77 | 2.92 ± 0.83* | 3.24 ± 0.95*† | 54.88 (F) | < 0.001 |
Alanine aminotransferase (U/L) | 22.54 ± 14.69 | 25.04 ± 16.66 | 22.92 ± 14.77* | 19.49 ± 12.85*† | 12.86 (F) | < 0.001 |
Blood urea nitrogen (mmol/L) | 5.3 [4.3, 6.5] | 4.9 [3.9, 6.1] | 5.3 [4.3, 6.5]* | 5.8 [4.6, 6.9]*† | 5.13 (Z) | < 0.001 |
Creatinine (mmol/L) | 74.0 [59.7, 88.4] | 75.0 [61.0, 89.2] | 74.1 [60.0, 88.6] | 70.5 [57.6, 85.6] | 2.83 (Z) | 0.018 |
Urine acid (mmol/L) | 279.6 [222.0, 344.6] | 260.0 [207.9, 330.0] | 279.8 [222.7, 346.0] | 282.1 [226.5, 337.4] | 2.05 (Z) | 0.122 |
Improved Framingham risk score (I-FRS) | 15.56 ± 4.01 | 6.37 ± 3.28 | 15.15 ± 2.36* | 21.40 ± 1.45*† | 3217.11 (F) | < 0.001 |
History of diseased | ||||||
DM | 867 (26.83%) | 124 (60.78%) | 723 (28.57%) | 20 (4.02%) | 262.29 (χ2) | < 0.001 |
HTN | 1436 (44.43%) | 62 (30.39%) | 1097 (43.34%) | 277 (55.73%) | ||
CVD | 929 (28.74%) | 18 (8.82%) | 711 (28.09%) | 200 (40.24%) | ||
Antihypertensive therapy | 1732 (53.59%) | 47 (23.04%) | 1270 (50.18%) | 415 (83.50%) | 267.19 (χ2) | < 0.001 |
Hypoglycemic therapy | 2928 (90.59%) | 169 (82.84%) | 2304 (91.03%) | 455 (91.55%) | 15.48 (χ2) | < 0.001 |
Sulfonylurea drugs | 1962 (60.71%) | 115 (56.37%) | 1555 (61.44%) | 292 (58.75%) | 2.97 (χ2) | 0.227 |
Metformin | 1430 (44.25%) | 73 (35.78%) | 1127 (44.53%) | 230 (46.28%) | 6.83 (χ2) | 0.033 |
Insulin therapy | 2097 (64.88%) | 120 (58.82%) | 1664 (65.74%) | 313 (62.98%) | 4.90 (χ2) | 0.086 |
Patients’ Clinical Characteristics
Patient characteristics | Framingham Risk Score stratificationa | Statistical quantityb | P valuec | ||
---|---|---|---|---|---|
I-FRS < 10% (n = 204 patients) | I-FRS ~ 10–20% (n = 2531 patients) | I-FRS > 20% (n = 497 patients) | |||
BMI (kg/m2) | 25.4 ± 3.6 | 25.2 ± 3.3 | 25.3 ± 3.2 | 0.36 (F) | 0.699 |
Waist circumference (cm) | 88.0 ± 9.7 | 87.7 ± 8.5 | 87.4 ± 8.5 | 0.21 (F) | 0.808 |
Hip circumference(cm) | 98.8 ± 9.9 | 97.7 ± 8.3 | 97.2 ± 8.0 | 1.55 (F) | 0.212 |
Neck circumference (cm) | 36.7 ± 3.4 | 36.6 ± 3.5 | 35.5 ± 3.3*† | 11.26 (F) | < 0.001 |
SBP (mmHg) | 125.3 ± 9.6 | 125.6 ± 8.3 | 128.6 ± 9.3*† | 14.46 (F) | < 0.001 |
DBP (mmHg) | 74.6 ± 6.6 | 73.8 ± 6.4a | 72.5 ± 7.4*† | 5.86 (F) | 0.003 |
FPG (mmol/L) | 7.56 ± 2.41 | 7.59 ± 2.11 | 7.66 ± 2.18 | 0.13 (F) | 0.876 |
Hpg (mmol/L) | 9.26 ± 2.39 | 9.17 ± 2.03 | 9.16 ± 2.07 | 0.08 (F) | 0.923 |
HbA1c (%) | 7.07 ± 1.37 | 7.09 ± 1.16 | 7.14 ± 1.12 | 0.19 (F) | 0.831 |
TG (mmol/L) | 1.60 ± 0.85 | 1.56 ± 0.77 | 1.75 ± 0.84 | 5.44 (F) | 0.004 |
TC (mmol/l) | 4.62 ± 1.00 | 4.47 ± 1.00 | 4.75 ± 1.10† | 8.09 (F) | < 0.001 |
HDL-cholesterol (mmol/L) | 1.35 ± 0.36 | 1.33 ± 0.47 | 1.35 ± 0.32 | 0.20 (F) | 0.819 |
LDL-cholesterol (mmol/L) | 2.61 ± 0.78 | 2.45 ± 0.73 | 2.57 ± 0.86 | 4.20 (F) | 0.015 |
Alanine aminotransferase (U/L) | 19.2 [15.0, 25.0] | 19.0 [15.0, 24.0] | 19.0 [14. 3,23.0] | 0.59 (Z) | 0.838 |
Blood urea nitrogen (mmol/L) | 5.6 [4.6, 6.3] | 5.6 [4.8, 6.6] | 6.1 [5.2, 7.3]*† | 5.23 (Z) | < 0.001 |
Creatinine (mmol/L) | 68.0 [57.0, 77.6] | 71.0 [60.0, 83.2] | 71.0 [60.0, 83.1] | 1.75 (Z) | 0.218 |
Urine acid (mmol/l) | 300.0 [250.7, 355.0] | 306.0 [251.0, 358.0] | 296.5 [241.0, 353.0] | 1.07 (Z) | 0.563 |
Hypoglycemic therapy | 115 (90.55%) | 1524 (94.78%) | 279 (95.55%) | 4.70 (χ2) | 0.095 |
Sulfonylurea drugs | 18 (14.17%) | 313 (19.47%) | 52 (17.81%) | 2.41 (χ2) | 0.299 |
Metformin | 71 (55.91%) | 737 (45.83%) | 105 (35.96%) | 16.19 (χ2) | < 0.001 |
Insulin therapy | 28 (22.05%) | 443 (27.55%) | 89 (30.48%) | 3.17 (χ2) | 0.205 |
Changes in Patients’ FRS
All-Cause Endpoint Events after 10-Years of Follow-Up
Endpoint events | Total (n = 3232 patients) | Framingham Risk Score stratificationa | Statistical quantityb | P value | ||
---|---|---|---|---|---|---|
I-FRS < 10% (n = 204 patients) [/100 person-year] | I-FRS ~10–20% (n = 2531 patients) [/100 person-year] | I-FRS > 20% (n = 497 patients) [/100 person-year] | ||||
CVD events | 343 (10.61) | 5 (2.45) [0.25] | 266 (10.51) [1.05] | 72 (14.49) [1.45] | 22.22 (χ2) | < 0.001 |
Cardiovascular | 201 (6.22) | 5 (2.45) [0.25] | 158 (6.24) [0.62] | 38 (7.65) [0.76] | 6.70 (χ2) | 0.035 |
Myocardial infarction | 58 (1.79) | 1 (0.49) [0.05] | 49 (1.94) [0.19] | 8 (1.61) [0.16] | 2.35 (χ2) | 0.308 |
Unstable angina pectoris | 28 (0.87) | 3 (1.47) [0.15] | 22 (0.87) [0.09] | 3 (0.60) [0.06] | 0.03 (F) | 0.451 |
Install cardiac pacemaker | 6 (0.19) | 0 (0.00) [0.00] | 6 (0.24) [0.02] | 0 (0.00) [0.00] | 0.23 (F) | 0.727 |
Coronary stent implantation | 50 (1.55) | 1 (0.49) [0.05] | 40 (1.58) [0.16] | 9 (1.81) [0.18] | 1.74 (χ2) | 0.419 |
Coronary artery bypass grafting | 17 (0.53) | 0 (0.00) [0.00] | 14 (0.55) [0.06] | 3 (0.60) [0.06] | 0.08 (F) | 0.732 |
Heart failure hospitalization | 21 (0.65) | 0 (0.00) [0.00] | 12 (0.47) [0.05] | 9 (1.81) [0.18] | 0.00 (F) | 0.006 |
Cerebrovascular | 142 (4.39) | 0 (0.00) [0.00] | 108 (4.27) [0.43] | 34 (6.84) [0.68] | 16.56 (χ2) | < 0.001 |
Acute cerebral hemorrhage | 18 (0.56) | 0 (0.00) [0.00] | 16 (0.63) [0.06] | 2 (0.40) [0.04] | 0.07 (F) | 0.743 |
Lacunar infarction | 30 (0.93) | 0 (0.00) [0.00] | 25 (0.99) [0.10] | 5 (1.01) [0.10] | 0.03 (F) | 0.483 |
Acute cerebral infarction with limb movement disorder | 69 (2.13) | 0 (0.00) [0.00] | 46 (1.82) [0.18] | 23 (4.63) [0.46] | 20.45 (χ2) | < 0.001 |
Transient ischemic attack (TIA) | 22 (0.68) | 0 (0.00) [0.00] | 19 (0.75) [0.08] | 3 (0.60) [0.06] | 0.05 (F) | 0.717 |
Cardiac and cerebral vascular death | 90 (2.78) | 0 (0.00) [0.00] | 67 (2.65) [0.26] | 23 (4.63) [0.46] | 12.26 (χ2) | 0.002 |
Cardiac death | 63 (1.95) | 0 (0.00) [0.00] | 45 (1.78) [0.18] | 18 (3.62) [0.36] | 11.72 (χ2) | 0.003 |
Cerebral death | 27 (0.84) | 0 (0.00) [0.00] | 22 (0.87) [0.09] | 5 (1.01) [0.10] | 0.03 (F) | 0.447 |
Variables | CVD events | Cardiovascular events | Cerebrovascular events | Cardiac and cerebral vascular death |
---|---|---|---|---|
Gender | 0.73 (0.59–0.90) | 0.70 (0.53–0.92) | 0.77 (0.56–1.08) | 0.44 (0.29–0.67) |
Age (years) | 1.03 (1.02–1.05) | 1.04 (1.02–1.05) | 1.03 (1.01–1.05) | 1.10 (1.07–1.13) |
Duration of diabetes (years) | 1.02 (1.00–1.03) | 1.02 (1.00–1.04) | 1.02 (0.99–1.04) | 1.04 (1.01–1.06) |
Drug therapy | 1.37 (0.91–2.06) | 1.86 (1.01–3.42) | 0.98 (0.57–1.71) | 1.49 (0.65–3.41) |
BMI (kg/m2) | 1.04 (1.01–1.07) | 1.06 (1.02–1.10) | 1.01 (0.96–1.06) | 1.04 (0.98–1.10) |
Waist circumference (cm) | 1.03 (1.02–1.04) | 1.03 (1.02–1.05) | 1.02 (1.00–1.04) | 1.04 (1.02–1.06) |
Neck circumference (cm) | 1.03 (1.00–1.06) | 1.04 (1.00–1.08) | 1.02 (0.98–1.07) | 1.03 (0.98–1.09) |
SBP (mmHg) | 1.01 (1.01–1.02) | 1.01 (1.00–1.02) | 1.02 (1.01–1.03) | 1.02 (1.01–1.04) |
DBP (mmHg) | 0.99 (0.98–1.01) | 1.00 (0.98–1.01) | 0.99 (0.98–1.01) | 0.99 (0.96–1.01) |
FPG (mmol/L) | 1.01 (0.97–1.05) | 0.95 (0.90–1.01) | 1.07 (1.02–1.13) | 1.00 (0.93–1.09) |
Hpg (mmol/L) | 1.01 (0.99–1.02) | 1.00 (0.98–1.03) | 1.01 (1.00–1.03) | 1.01 (0.99–1.04) |
HbA1c (%) | 1.08 (1.01–1.14) | 1.03 (0.94–1.12) | 1.14 (1.05–1.24) | 1.16 (1.05–1.29) |
TG (mmol/L) | 1.04 (0.97–1.11) | 1.01 (0.91–1.11) | 1.07 (0.97–1.18) | 0.99 (0.85–1.15) |
TC (mmol/L) | 1.08 (1.00–1.16) | 1.03 (0.92–1.14) | 1.14 (1.04–1.25) | 0.95 (0.79–1.13) |
HDL-cholesterol (mmol/L) | 0.88 (0.67–1.15) | 0.60 (0.40–0.89) | 1.26 (0.92–1.74) | 0.47 (0.25–0.89) |
LDL-cholesterol (mmol/L) | 1.08 (0.95–1.22) | 1.16 (0.99–1.36) | 0.97 (0.80–1.18) | 0.97 (0.77–1.23) |
Alanine aminotransferase (10 U/L) | 0.99 (0.92–1.08) | 1.02 (0.92–1.13) | 0.95 (0.83–1.09) | 0.83 (0.68–1.03) |
Blood urea nitrogen (10 mmol/L) | 0.98 (0.89–1.08) | 0.92 (0.69–1.22) | 1.01 (0.92–1.11) | 1.02 (0.91–1.14) |
Creatinine (10 mmol/L) | 1.03 (0.99–1.06) | 1.01 (0.96–1.06) | 1.05 (1.00–1.11) | 1.05 (0.99–1.12) |
Urine acid (10 mmol/l) | 1.02 (1.01–1.03) | 1.02 (1.00–1.03) | 1.02 (1.00–1.03) | 1.02 (1.00–1.04) |
I-FRS | 1.09 (1.06–1.13) | 1.07 (1.04–1.11) | 1.12 (1.08–1.18) | 1.16 (1.09–1.22) |
Endpoint events | P | Hazard ratio | 95% Confidence interval for hazard ratio | |
---|---|---|---|---|
Lower | Upper | |||
CVD | ||||
I-FRS | 0.001 | |||
10–20% vs. < 10% | 0.003 | 3.89 | 1.60 | 9.47 |
>20% vs. < 10% | 0.000 | 5.25 | 2.09 | 13.16 |
Cardiovascular | ||||
I-FRS | 0.150 | |||
10–20% vs. < 10% | 0.072 | 2.29 | 0.93 | 5.64 |
>20% vs. < 10% | 0.052 | 2.60 | 0.99 | 6.79 |
Cerebrovascular | ||||
I-FRS | 0.005 | |||
10%-20% vs. < 10% | 0.041 | 7.82 | 1.08 | 56.35 |
>20% vs. < 10% | 0.012 | 12.93 | 1.75 | 95.84 |
Cardiac and cerebral vascular death | ||||
I-FRS | 0.087 | |||
10%-20% vs. < 10% | 0.186 | 3.81 | 0.52 | 27.79 |
>20% vs.< 10% | 0.088 | 5.81 | 0.77 | 43.90 |
Endpoint events | No decrease in BMI (n = 2371 patients) | Yes decrease in BMI (n = 861 patients) | Statistical quantitya | P |
---|---|---|---|---|
CVD events | 254 (10.71) | 89 (10.34) | 0.09 (χ2) | 0.759 |
Cardiovascular | 143 (6.03) | 58 (6.74) | 0.54 (χ2) | 0.463 |
Myocardial infarction | 51 (2.15) | 7 (0.81) | 6.42 (χ2) | 0.011 |
Unstable Angina pectoris | 16 (0.67) | 12 (1.39) | 3.80 (χ2) | 0.051 |
Install cardiac pacemaker | 3 (0.13) | 3 (0.35) | 0.15 (F) | 0.196 |
Coronary stent implantation | 27 (1.14) | 23 (2.67) | 9.74 (χ2) | 0.002 |
Coronary artery bypass grafting | 8 (0.34) | 9 (1.05) | 0.01 (F) | 0.024 |
Heart failure hospitalization | 19 (0.80) | 2 (0.23) | 3.17 (χ2) | 0.075 |
Cerebrovascular | 111 (4.68) | 31 (3.60) | 1.76 (χ2) | 0.185 |
Acute cerebral hemorrhage | 16 (0.67) | 2 (0.23) | 0.08 (F) | 0.183 |
Lacunar infarction | 26 (1.10) | 4 (0.46) | 2.74 (χ2) | 0.098 |
Acute cerebral infarction with limb movement disorder | 55 (2.32) | 14 (1.63) | 1.45 (χ2) | 0.228 |
Transient ischemic attack (TIA) | 12 (0.51) | 10 (1.16) | 4.01 (χ2) | 0.045 |
All-cause death | 185 (7.80) | 3 (0.35) | 64.06 (χ2) | <0.001 |
Cardiac and cerebral vascular death | 89 (3.75) | 1 (0.12) | 30.87 (χ2) | <0.001 |
Cardiac death | 62 (2.61) | 1 (0.12) | 20.63 (χ2 | <0.001 |
Cerebral death | 27 (1.14) | 0 (0.00) | 9.89 (χ2) | 0.002 |